Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$3.69B |
| 2 |
Abbott
ABT
|
+$3.65B |
| 3 |
Qualcomm
QCOM
|
+$3.54B |
| 4 |
Procter & Gamble
PG
|
+$3.42B |
| 5 |
Accenture
ACN
|
+$3.28B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$2.86B |
| 2 |
AbbVie
ABBV
|
+$2.71B |
| 3 |
Valero Energy
VLO
|
+$1.86B |
| 4 |
Lockheed Martin
LMT
|
+$916M |
| 5 |
Halliburton
HAL
|
+$856M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 10.68% |
| 3 | Healthcare | 10.19% |
| 4 | Industrials | 8.63% |
| 5 | Consumer Discretionary | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Insteel Industries
IIIN
$638M
| $11.8M | ﹤0.01% |
350,022
-16,745
| -5% | -$574K |
|
2027
TransAlta
TAC
$4.23B
| $11.8M | ﹤0.01% |
896,927
+2,803
| +0.3% | +$36.1K |
|
2028
Ultragenyx Pharmaceutical
RARE
$2.67B
| $11.7M | ﹤0.01% |
558,486
-40,438
| -7% | -$911K |
|
2029
Recursion Pharmaceuticals
RXRX
$1.63B
| $11.7M | ﹤0.01% |
3,808,798
-185,853
| -5% | -$718K |
|
2030
QCR Holdings
QCRH
$1.66B
| $11.6M | ﹤0.01% |
136,287
-3,045
| -2% | -$265K |
|
|
BRSP
2031
BrightSpire Capital
BRSP
$684M
| $11.6M | ﹤0.01% |
2,078,470
-163,791
| -7% | -$948K |
|
2032
Kforce
KFRC
$1.01B
| $11.6M | ﹤0.01% |
396,578
-496,986
| -56% | -$15.1M |
|
2033
Core Laboratories
CLB
$531M
| $11.5M | ﹤0.01% |
686,950
-50,600
| -7% | -$905K |
|
2034
Marcus & Millichap
MMI
$1.18B
| $11.5M | ﹤0.01% |
433,613
+48,497
| +13% | +$1.28M |
|
|
GLIBK
2035
Liberty Capital Corp Series C GCI Group Common Stock
GLIBK
$895M
| $11.5M | ﹤0.01% |
309,840
+86,482
| +39% | +$3.27M |
|
2036
Harmony Biosciences
HRMY
$2.1B
| $11.5M | ﹤0.01% |
411,597
-6,358
| -2% | -$208K |
|
2037
United States Lime & Minerals
USLM
$3.19B
| $11.5M | ﹤0.01% |
88,033
-331
| -0.4% | -$39.8K |
|
2038
Procept Biorobotics
PRCT
$998M
| $11.4M | ﹤0.01% |
457,056
-5,317
| -1% | -$150K |
|
2039
Genesco
GCO
$411M
| $11.4M | ﹤0.01% |
393,914
-15,313
| -4% | -$440K |
|
2040
Hertz
HTZ
$584M
| $11.4M | ﹤0.01% |
2,465,313
-69,591
| -3% | -$337K |
|
2041
Bank First Corp
BFC
$1.67B
| $11.3M | ﹤0.01% |
83,967
+9,203
| +12% | +$1.25M |
|
2042
Heartland Express
HTLD
$1.08B
| $11.3M | ﹤0.01% |
1,089,550
-666
| -0.1% | -$7.03K |
|
2043
AvePoint
AVPT
$2.69B
| $11.3M | ﹤0.01% |
1,189,775
-661
| -0.1% | -$7.44K |
|
2044
Red Cat Holdings
RCAT
$1.18B
| $11.3M | ﹤0.01% |
862,344
-2,636
| -0.3% | -$36K |
|
2045
Novavax
NVAX
$1.27B
| $11.2M | ﹤0.01% |
1,373,505
+38,452
| +3% | +$349K |
|
2046
Azenta
AZTA
$1.28B
| $11.1M | ﹤0.01% |
527,611
-34,990
| -6% | -$1.05M |
|
2047
Relay Therapeutics
RLAY
$4.12B
| $11.1M | ﹤0.01% |
1,111,891
-24,811
| -2% | -$222K |
|
2048
Winmark
WINA
$1.22B
| $11M | ﹤0.01% |
25,794
+991
| +4% | +$437K |
|
2049
US Physical Therapy
USPH
$1.14B
| $11M | ﹤0.01% |
146,968
-920
| -0.6% | -$75.4K |
|
2050
Zumiez
ZUMZ
$330M
| $11M | ﹤0.01% |
496,787
-19,262
| -4% | -$469K |
|
Similar funds
Charles Schwab's Q1 2026 Portfolio in Review
As of Q1 2026, Charles Schwab held 3,535 positions worth $654B, up 1.7% from $644B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab deployed $21.4B of net new capital in Q1 2026, opening 79 new positions and adding to 1,903 existing holdings. Its largest new stake was JPMorgan Income ETF: 8,679,689 shares worth $400M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Cisco, an estimated $2.86B trimmed.
- Charles Schwab's largest Q1 2026 buy was JPMorgan Income ETF: 8,679,689 shares worth $400M.
- Charles Schwab added most to UnitedHealth in Q1 2026, an estimated $3.69B increase.
- Charles Schwab's biggest Q1 2026 reduction was Cisco, cutting an estimated $2.86B.
- Charles Schwab fully exited Comerica in Q1 2026, selling an estimated $412M.
- Charles Schwab's ten largest holdings make up 22% of its $654B portfolio in Q1 2026.
- Charles Schwab opened 79 new positions and closed 80 in Q1 2026.
- Charles Schwab's portfolio value rose 1.7% quarter-over-quarter to $654B.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.